Cell And Gene Therapy Videos

31. CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D. 9/9/2025

    Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

32. Extractables, Leachables, And Risk: Ensuring Safety In Pharma Manufacturing 9/8/2025

    This session is designed for teams developing new products, optimizing processes, or preparing regulatory submissions, and will provide practical tools for a better approach to E&L management.

33. Solving Fragmentation: Future-Proofing The Advanced Therapy Supply Chain 9/5/2025

    Whether you are preparing for your first clinical shipment or scaling for global distribution, this conversation provides strategies to streamline operations, improve reliability, and deliver better patient outcomes.

34. PEI And Non-PEI Transfection Solutions For High Titers And Production 9/2/2025

    Discover optimized AAV production with polyethylenimine (PEI) and non-polyethylenimine transfection solutions that are designed to boost titers and streamline scalability.

35. How CRISPR And LNP Accelerate Therapeutic Innovation Through Analytics 9/2/2025

    CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.

36. Enabling CTA Submission In Record Time: Adenovirus Program Success 8/25/2025

    What does it take to bring an adenovirus-based therapy to the clinic – faster and without compromising quality? Find actionable insights to help improve efficiency and accelerate development timelines.

37. Donor-To-Dose Solutions For Scalable Cell Therapy Manufacturing 8/21/2025

    From enabling earlier insights through donor characterization to reducing manufacturing variability through cell separation technologies, explore real-world case studies and actionable approaches to scale smarter.

38. Viralgen Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.

39. Minaris Advanced Therapies Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, Minaris delivers speed, scalability, and reliability to help therapeutic developers bring cures to patients faster.

40. Excellos Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    Excellos leverages its extensive starting material expertise as a key differentiator. Explore how our deep understanding of partner-sourced raw materials, quality control, and supply chain management creates significant value for our clients.